{"type":"trials","record":{"id":41508,"source_id":"clinicaltrials-gov","external_id":"NCT06864988","title":"4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","brief_summary":"A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration","overall_status":"Active Not Recruiting","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"4D Molecular Therapeutics","enrollment":480,"countries":["United States","Canada"],"start_date":"2025-03-03","completion_date":"2028-06-01","last_update_date":"2026-06-01","source_url":"https://clinicaltrials.gov/study/NCT06864988","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Aflibercept (AFLB) 2 mg IVT","organization":"4D Molecular Therapeutics","interventions":["4D-150 IVT (3E10 vg/eye)","EYLEA® (aflibercept) Injection 2 mg (0.05mL)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change from baseline in BCVA ETDRS letter score at Week 52 — 52 Weeks","Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104 — 104 Weeks","Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104 — 104 Weeks","Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm — 1…","Mean change from baseline in CST over time through Weeks 52 and 104 — 104 Weeks","Mean change from baseline in BCVA ETDRS letter score over time through Weeks 52 and 104 — 104 Weeks"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Macular Neovascularization Secondary to Age-Related Macular Degeneration","4D-150 IVT (3E10 vg/eye)","EYLEA® (aflibercept) Injection 2 mg (0.05mL)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06864988","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2025-03-03 to 2028-06-01","comparator":"Aflibercept (AFLB) 2 mg IVT","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.824Z","intervention":["4D-150 IVT (3E10 vg/eye)","EYLEA® (aflibercept) Injection 2 mg (0.05mL)"],"participants":480,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change from baseline in BCVA ETDRS letter score at Week 52 — 52 Weeks","Mean annualized number of aflibercept injections after Week 4 through Weeks 52 and 104 — 104 Weeks","Incidence and timing of aflibercept injections after Week 4 through Weeks 52 and 104 — 104 Weeks","Proportion of subjects not requiring aflibercept injections after Week 4 through Weeks 52 and 104 in the 4D-150 arm — 1…","Mean change from baseline in CST over time through Weeks 52 and 104 — 104 Weeks","Mean change from baseline in BCVA ETDRS letter score over time through Weeks 52 and 104 — 104 Weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41508","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}